Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients

Funda Erduran,Selma Emre,Yıldız Hayran,Esra Adışen,Asude Kara Polat,Pelin Üstüner, Serap Öztürkcan,Perihan Öztürk,Aylin Türel Ermertcan,Leyla Baykal Selçuk, Esra Koku Aksu,Ayşe Akbaş,Göknur Kalkan,Deniz Demirseren,Selda Pelin Kartal,Zeynep Topkarcı,Arzu Kılıç,Mahizer Yaldız,Sema Aytekin,Pelin Hızlı, Sheyda Gharehdaghi,Murat Borlu, Lütfi Işık, Bengü Reyhan Botsalı,Eda Öksüm Solak,Hülya Albayrak,Melis Gönülal,Didem Didar Balcı,Mualla Polat,Munise Daye,Arzu Ataseven, Sibel Yıldız,İlkay Özer,Özge Zorlu,Sinan Doğan,Vefa Aslı Erdemir,Bahar Sevimli Dikicier

Archives of Dermatological Research（2024）

引用 0|浏览4

暂无评分

摘要

Methotrexate (MTX) is commonly used as first-line systemic treatment agent in psoriasis. We aimed to evaluate the clinical characteristics and treatment responses of patients with psoriasis undergoing MTX monotherapy. Data from adult patients with plaque psoriasis who received MTX monotherapy for at least 3 months between April 2012 and April 2022 were retrospectively evaluated in 19 tertiary care centers. Our study included 722 female and 799 male patients, a total of 1521 participants. The average age of the patients was 44.3 ± 15.5 years. Mode of treatment was oral in 20.4

查看译文

关键词

Psoriasis,Methotrexate,Subcutaneous,PASI 90,Side effects

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要